Evidence map›Paper›PMID 25886924›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.

Max R OʼDonnell, Melendhran Pillay, Manormoney Pillay, Lise Werner, Iqbal Master, Allison Wolf, Barun Mathema, Yacoob M Coovadia, Koleka Mlisana, Charles Robert Horsburgh and 1 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Max R OʼDonnell*Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY; †Department of Epidemiology, Columbia Mailman School of Public Health, New York, NY; ‡Centre for AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; §Department of Microbiology, National Health Laboratory Service (NHLS), Durban, South Africa; ‖Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; ¶DR-TB Department, King Dinuzulu Hospital, Department of Health, Sydenham, South Africa; and #Department of Epidemiology, Boston University School of Public Health, Boston, MA.
Melendhran Pillay
Manormoney Pillay
Lise Werner
Iqbal Master
Allison Wolf
Barun Mathema
Yacoob M Coovadia
Koleka Mlisana
Charles Robert Horsburgh
Nesri Padayatchi
Columbia University · USNational Health Laboratory Service · ZACentre for the AIDS Programme of Research in South Africa · ZAUniversity of KwaZulu-Natal · ZA

Funding

Biomarker for XDR-TB Treatment Response and Drug Resistance in HIV Endemic AreaK23AI098479 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · 2012 to 2016
$669k
NIAID NIH HHS K23 AI098479PHS HHS A1069469
6 · The paper itself

Abstract

backgroundCapreomycin is a key antimycobacterial drug in treatment of extensively drug-resistant tuberculosis (XDR-TB). Drug-susceptibility testing (DST) for capreomycin is not routinely performed in newly diagnosed XDR-TB in South Africa. We performed this study to assess the prevalence, clinical significance, and molecular epidemiology of capreomycin resistance in newly diagnosed patients with XDR-TB in KwaZulu-Natal, South Africa.

methodsRetrospective cohort study of consecutive patients with XDR-TB admitted to a TB referral hospital without previous XDR-TB treatment. A subset of isolates had extended DST (including capreomycin), mutational analysis, and IS6110 restriction fragment length polymorphism assays.

resultsA total of 216 eligible patients with XDR-TB were identified. The majority were treated with capreomycin (72%), were young (median age: 35.5 years), and were female (56%). One hundred five (76%) were HIV+, and 109 (66%) were on antiretroviral therapy. A subset of 52 patients had full DST. A total of 47/52 (90.4%) patients with XDR-TB were capreomycin resistant. Capreomycin-resistant patients experienced worse mortality and culture conversion than capreomycin susceptible, although this difference was not statistically significant. The A1401G mutation in the rrs gene was associated with capreomycin resistance. The majority of capreomycin-resistant strains were F15/LAM4/KZN lineage (80%), and clustering was common in these isolates (92.5%).

conclusionsCapreomycin resistance is common in patients with XDR-TB in KwaZulu-Natal, is predominantly because of ongoing province-wide transmission of a highly resistant strain, and is associated with high mortality. Capreomycin should be included in routine DST in all patients with XDR-TB. New drug regimens that do not include injectable agents should be operationally tested as empiric treatment in XDR-TB.

Indexed as

AdultAntibiotics, AntitubercularAnti-HIV AgentsCapreomycinCohort StudiesDrug Resistance, MicrobialDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleGenotypeHIV InfectionsHumansMaleMycobacterium tuberculosisRetrospective StudiesSouth AfricaAntibiotics, AntitubercularAnti-HIV AgentsCapreomycin

Identifiers

PMID25886924
PMCPMC4501864
OpenAlexW2415099463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.